OmniAb, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $OABI in the last 30 days.
See all $OABI insider activity →OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
OmniAb (OABI) and Eli Lilly (LLY) announced a global collaboration to develop ion channel therapeutics. Lilly will pay $370M in milestones plus royalties. OABI reported Q2 2026 revenue of $13.4M, up from $3.9M, while LLY reported $23B revenue, up 48% YoY. OABI's model focuses on licensing, while LLY's growth is driven by GLP-1 treatments.
Biotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.
Over the past 7 days, alphai's AI scored 1 news story mentioning OABI (OmniAb, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent OABI coverage spans market movers, mergers & acquisitions and earnings.
Positive guidance and increased platform spend suggest higher future revenue, supporting short‑term upside.
The deal gives OmniAb non‑dilutive capital and future royalty upside, likely supporting its share price.
Guidance raise and cash outlook improvement are likely to support near-term momentum, but upside depends on follow-through on clinical and commercialization.
Higher expected cash runway should reduce near-term dilution risk and support continued investment, likely sustaining bullish momentum.
Material positive read-through from a Lilly partnership plus improved runway, though economics depend on undisclosed target/modality.
alphai scores every news story that mentions OABI with an AI model for sentiment and relevance, and aggregates insider trades from OmniAb, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
OmniAb (OABI) +13% to $5.43, raising 2026 cash flow guidance to $49M-$53M. Freenome (FRNM) +4% to $16.03 after FDA approvals. Exelixis (EXEL) +$59.11, Q2 profit $212M. LifeStance (LFST) +$13.15, Q2 revenue +26% to $435.4M. Faeth (FTH) +$40.89, Q2 loss $16M.
2 min readOmniAb (OABI) and Eli Lilly (LLY) announced a global collaboration to develop ion channel therapeutics. Lilly will pay $370M in milestones plus royalties. OABI reported Q2 2026 revenue of $13.4M, up from $3.9M, while LLY reported $23B revenue, up 48% YoY. OABI's model focuses on licensing, while LLY's growth is driven by GLP-1 treatments.
3 min readBiotech shares hit 52-week highs on Aug. 17, 2026. OmniAb (OABI) rose to $4.29 after raising 2026 cash flow guidance; Q2 revenue was $13.4M. Iovance (IOVA) reached $7.25 on Q2 revenue growth to $66M and Amtagvi sales. Revolution (RVMD) hit $215.97 on Phase 3 RASolute data for Daraxonrasib. BioLife (BLFS) hit $35.46 after Repligen (RGEN) agreed to buy it for about $1.5B.
5 min readOmniAb Inc. (OABI) shares rose about 18% in premarket after the company increased its 2026 cash forecast. OmniAb now expects $49 million to $53 million in cash and cash equivalents, up from $37 million to $41 million, citing recent license and business-development agreements, including a technology contract with Eli Lilly for its ion-channel program.
3 min readBiotech gainers were led by 4D Molecular Therapeutics (FDMT), up over 12%, after Phase 3 enrollment progress for 4D-150 in wet AMD and other pipeline updates, plus a $200M credit facility. OmniAb (OABI) rose over 11% on an Eli Lilly collaboration and higher 2026 cash guidance. Acurx (ACXP) gained over 14% after FDA conditional acceptance of CIFBEZY as ibezapolstat’s brand name.
7 min readOmniAb Inc. (NASDAQ: OABI) shares rose about 21.6% after the company reported a Q2 earnings beat and raised 2026 revenue guidance to $32M–$36M from $28M–$33M. The article cites Q2 revenue around $13.4M, gross margin near 99.9%, and positive operating and free cash flow. It also notes a Veraxa Biotech collaboration on VXA-222.
6 min readInvesting.com reports OmniAb’s shares rose 22.5% in pre-open trading to $4.14, above its prior 52-week high of $3.635. The company announced a global collaboration and license with Eli Lilly for an ion channel drug discovery program, with an upfront payment and up to $370M in milestones plus tiered royalties. OmniAb also raised 2026 cash guidance to $49M-$53M from $37M-$41M.
4 min readOmniAb, Inc. (OABI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 OmniAb Reports Second Quarter 2026 Financial Results and Business Highlights Raises Full Year 2026 Revenue and Cash Outlook Driven by Continued Business Momentum Conference Call to Begin Today at 4:30 p.m. ET EMERYVILLE, Calif. (August 6, 2026) – OmniAb, Inc. (NASDAQ
6 min readOmniAb Inc (NASDAQ:OABI) shares rose about 7.6% premarket after it named Amechi Nwachuku as Executive VP and Chief Operating Officer, a newly created role. He will oversee strategy, operations and commercial development of the xPloration B-cell screening platform. OmniAb said its licensing business remains strong with milestone and royalty programs.
3 min readOmniAb, Inc. (OABI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. oabi-20260713 FALSE 0001846253 Nasdaq 0001846253 2026-06-17 2026-06-17 0001846253 us-gaap:CommonStockMember 2026-06-17 2026-06-17 0001846253 us-gaap:WarrantMember 2026-06-17 2026-06-17 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K
2 min read
